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Abstract 
Methylchloroisothiazolinone (MCI) and methylisothiazolinone (MI) are biocides used in many 
types of products such as cosmetics, paints, and cleaning agents. Skin contact is often 
encountered when using these products. Although MCI and MI are strong allergens and cause 
skin irritation, no scientific skin permeation study has been reported except for some 
unpublished data. Therefore, this study assessed the permeation of MCI and MI both separately 
and as a mixture through freshly dermatomed human skin (800 µm) in a flow-through diffusion 
cell system. Different concentrations of aqueous standards (1.5/1, 70/50, 150/35, and 750/175 
µg/mL of MCI/MI) and various commercial products were assessed after 15 to 20 hours of 
exposure. In parallel, the dose dependent irritant effects of MCI/MI and MI were estimated by 
histology following 6-h or 24-h exposure. Overall results show that MI in formulations or in 
aqueous standard solutions quickly permeated the skin with time lags less than 15 minutes 
while MCI was much slower (>3.5 h). MCI in formulations had permeation rates up to five times 
greater than for MI in the same product, and in two tested creams were not found to permeate 
skin. Some signs of irritation were observed by histology; especially at the highest MCI/MI 
concentrations (750/205 µg/mL) in aqueous solutions. This confirms that MCI reacts readily with 
skin and may induce local irritation. The MCI and MI permeations are also greatly influenced by 
the topical vehicle. It is therefore more relevant to test exposures to formulations than aqueous 
standard solutions. 
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Introduction 
Isothiazolinones are extensively used and have been since the 1970s (Douglas 2010). They are 
frequently used in various industrial products (e.g., paints, oils, glues, adhesives, detergents, 
inks, polishes, water-cooling systems), leave-on and rinse-off cosmetics, and aqueous-based 
household products (e.g., water-based paints, cleaning and washing agents) (Ackermann et al. 
2011; Alexander 2002; Castanedo-Tardana and Zug 2013; Devos et al. 2015). A solution of 
methylchloroisothiazolinone (MCI) and methylisothiazolinone (MI) mixed in a 3:1 ratio and MI 
alone are both commonly used as preservatives in products. In the Danish Product Register 
Database (PROBAS), the MCI/MI mixture was the third most frequent isothiazolinone (611 
different products) after MI (884 different products) and benzisothiazlinone; and before MCI (474 
different products) (Friis et al. 2014). MCI/MI concentrations are far greater in industrial products 
(1.5% - 13.5%) than in cosmetics (7.5 ppm or µg/mL) or domestic products (15 ppm or µg/mL) 
(Castanedo-Tardana and Zug 2013; Reinhard et al. 2001; Urwin et al. 2015). Hairdressers, 
beauticians, mechanics, repairmen, machinists, painters, paint factory workers, and restaurant 
workers have extensive exposures (Vauhkala et al. 2015). 
Like all isothiazolinone compounds, MCI and MI have a heterocyclic sulphur with an activated 
N-S bond making them electrophilic (see the physico-chemical properties in Table 1) (Alexander 
2002; Alvarez-Rivera et al. 2012). This electrophilic N-S bond reacts with nucleophilic cell 
material and oxidizes compounds containing thiols (Alvarez-Rivera et al. 2012). It is this 
electrophilic property that gives them a powerful antimicrobial activity against a broad-spectrum 
of bacteria, yeasts, fungi, and algae; even at very low concentrations and over very broad pH 
ranges (Ackermann et al. 2011; Alvarez-Rivera et al. 2012; De Bethizy et al. 1986). 
MCI and MI are considered high potent contact allergens and are one of the most common 
causes of contact allergy and dermatitis induced by preservatives (Braun-Falco et al. 2008; 
Castanedo-Tardana and Zug 2013). Several studies have reported airborne contact dermatitis 
after recent exposure to water-based paint containing MCI and MI (e.g., Bohn et al. (2000); 
Braun-Falco et al. (2008); Breuer et al. (2015); Lundov et al. (2014); Reinhard et al. (2001); 
Wright and Cahill (2015)). Furthermore, various studies and case reports have described 
allergic contact dermatitis (ACD) following skin exposure (e.g., Ackermann et al. (2011); Carlsen 
et al. (2008); Cleenewerck (2008); Lundov et al. (2011); Mendonca et al. (2014); Puangpet et al. 
(2015)). Although no clear thresholds are defined, skin effects are dose-dependent where low 
concentrations can result in ACD and high concentrations can induce severe burns as well as 
sensitization (Bayraktar and Ozcan 2007; Cleenewerck 2008). In the early 2000s, MCI was 
4 
recognized as an extreme skin sensitizer, while MI was considered as a weak sensitizer. This 
has resulted in an increase of MI use as it the MCI/MI mixture. However, MI was later deemed 
as a strong sensitizer (Devos et al. 2015). This substitution was also made for cosmetic 
products which authorized a MI concentration limit of 100 µg/mL (Castanedo-Tardana and Zug 
2013; Devos et al. 2015). Even after this substitution was made, the number of ACD cases kept 
increasing as did the prevalence of sensitization due to MCI/MI and MI. Occupational ACD 
caused by MCI/MI or/and MI are especially frequent among beauticians, hairdressers and 
healthcare workers as described in the retrospective study by Gameiro et al. (2014). This study 
reported with an increase in prevalence from <1% in 2005 to 10.9% in 2013 of which 51.4% 
were related to professional activities. Furthermore, Urwin et al. (2015) reported an increase in 
incidence of 4.1% per annum from 1996 to 2012. MI is now considered a strong sensitizer 
(Devos et al. 2015). 
Despite their extensive use, MCI and MI exposure data are lacking. No study was identified in 
the scientific literature on MCI/MI skin permeation rate; although, some unpublished data from 
Rohm and Haas on skin permeation rates in animals or in post mortem human skin from Rohm 
and Haas have been reported by Burnett et al. (2010) and SCCS (2009). In the present study, 
MCI and MI permeation properties were assessed separately, and as a mixture in standard 
solutions or in commercial formulations using viable human skin ex vivo, mounted on a flow-
through diffusion cell system. Structural changes in the epidermis were determined by histology 
when full thickness viable human skin was used and a quantitative dose-response was obtained 
for irritation. 
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Materials and methods 
Chemicals and supplies 
The methylchloroisothiazolinone (5-chloro-2-methyl-4-isothiazolin-3-one; MCI; CAS 26172-55-4; 
purity of 99%) and the methylisothiazolinone (2-methyl-4-isothiazolin-3-one; MI; CAS 2682-20-4; 
purity of 98.2%) were bought from Dr. Ehrenstorfer GmbH (Augsburg, Germany). The internal 
standard 6-deuterated isoproturon (isoproturon-d6, CAS 217487-17-7, 99.8% purity) was 
obtained from Sigma Aldrich (Pestanal®, Buchs, Switzerland). In addition, ammonium acetate 
(>98% purity) were purchased from Merk (Zug, Switzerland) and sodium chloride (NaCl) (>99% 
purity) from Fluka (Sigma-Aldrich, Buchs, Switzerland). For skin irritation appraisal test, RPMI 
1640 media (HEPES Modification, with 25 mM HEPES, without L-glutamine) was purchased 
from Sigma-Aldrich (Buchs, Switzerland). Methanol (MeOH) was analytical grade and 
purchased from Sigma-Aldrich (Buchs, Switzerland). All stock and working solutions were 
prepared in purified water (TKA GenPure water treatment system (TKA 
Wasseraufbereitungsszsteme GmbH, Niederelbert, Germany). Solid-phase extraction cartridges 
(Isolute ENV+, 100 mg, 3 mL) were obtained from Biotage (Uppsala, Sweden). The following 
four commercially available products were kindly provided by the manufacturers: a fungicide to 
treat swimming pool water (Revaguard® Plus, Mareva, Saint-Martin de Crau, France;14% 
MCI/MI mixture (3:1)), liquid used to preserve a broad range of water based products 
(Parmetol® K40, Schülke & Mayr AG, Zürich, Switzerland; 1.7% MCI/MI mixture (3:1)), two 
moisturizing creams for occupational use (MR Extra®, Sorein-fabrik GmbH, Pfäffikon, 
Switzerland and Priva Care®, Minatol Werke AG, Kloten, Switzerland). No information was 
provided on the composition of the two creams. 
 
Human skin 
Human abdominal full thickness skin from Caucasian females (age range 37-54 years) was 
obtained as surgical waste from abdominoplasty surgeries from the Lausanne university 
hospital (CHUV) and the Department of Musculoskeletal Medicine (DAL) biobank, under 
anonymous donation, in accordance with its regulation and accepted by the cantonal ethics 
committee under protocol 264/12. The full thickness skin was collected immediately following 
surgery, rinsed with physiological water (saline water; 0.9% sodium chloride (NaCl) (>99% 
purity, Sigma-Aldrich, Buchs, Switzerland) in purified water, dermatomed to a thickness of 0.8 
mm using an electrical dermatome (Acculan®II, B. Braun/Aesculap, Sempach, Switzerland), 
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and cut into circular discs. No more than 2 hours elapsed from the surgery-end to the skin was 
mounted on the flow-through diffusion cells. Full thickness skin was used for the irritation 
appraisal. 
 
Flow-through diffusion cell experiments 
A rack of six jacketed flow-through diffusion cells (PermGear®, SES Analytical System, 
Bechenheim, Germany) was used. Receptor compartments (12 mL) were filled with 
physiological solution and kept at 32°C using a recirculating water bath and a jacket surrounding 
each cell. The system was operated at a rate of 2.4 mL/h by a peristaltic pump (8 channels, 
Ismatec IPC-N, IDEX Health & Science GmbH, Wertheim-Mondfeld, Germany). Six skin discs 
(skin area exposed was 1.77 cm2) from each donor were stabilized in the system for 
approximately 30 minutes prior to topical applications of standard solutions or commercial 
products. The skin barrier integrity was assessed by measuring the transepidermal water loss 
(TEWL; mean measured value was 7.5 ± 2.7 g/m2/h) using a VapoMeter (Delfin Technologies 
Ltd., Kuopio, Finland). Skin discs with values above 11 g/m2/h were deemed damaged and 
replaced before starting the experiment. Infinite doses (i.e., the added volume of the tested 
compounds were sufficient for the complete experiment time) of MCI and MI standard solutions 
(from cosmetic up to industrial product range concentrations) as well as four different products, 
pure or diluted in water were applied, separately (Table 2 summarizes the tested products and 
the doses applied). MCI/MI standard solutions were prepared by adding and mixing MCI and MI 
stock solutions (100 µL of each stock solution) and then diluting in 9.8 mL of purified water. To 
quantify the dose of the cream applied on the top of the skin, plastic graded pipettes were 
weighted, filled with approximately 1 mL of cream, and then re-weighted. The difference in 
weight was used as the amount of cream applied. The applied cream was spread by rubbing the 
pipette on the skin thus simulating the use of skin cream. Lastly, the pipette was reweighted to 
quantify the dose applied on the skin. For both creams CMI and MI were listed on the ingredient 
label, but no quantitative information was available. To calculate a dose, an assumption of 15 
ppm was made which is the maximal concentration recommended by the European Cosmetic 
Products legislation (Directive 76/768/EEC, subsequently Regulation (EC) 1223/2009). 
The exposed skin area was 1.77 cm2. Skin samples were not occluded. The reservoir liquid was 
automatically sampled by a fraction collector (FC 204, Gilson Inc., Middleton, WI, USA) before 
experiment started (contamination check) and at 2, 4, 6, 8, 10, 12, 15 and 20 h after product 
application. All assays were performed in agreement with the Organization for Economic Co-
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operation and Development (OECD) guidelines 28 and 428 (OECD 2004a; OECD 2004b). 
These guidelines do not include procedures for washing and applied dose estimates for creams. 
 
MCI and MI quantification 
MCI and MI were extracted from the reservoir liquid using solid phase extraction (SPE) 
cartridges. First, the cartridges were washed, (2 mL of MeOH, followed with 2 mL of ammonium 
acetate (50 mM, pH 6)) then a 2-mL aliquot of reservoir liquid spiked with 100 µL of isoproturon 
6-d internal standard (52 µg/mL in MeOH) was passed through the SPE cartridge. The 
cartridges were washed with 1 mL of purified water and dried using a positive pressure manifold 
(Biotage® Pressure + 48, Biotage, Uppsala, Sweden) at a flow rate of 2 mL/min. Washed (with 
0.5 mL of MeOH) 45 μm PTFE filters were added directly to the SPE cartridge, before eluting 
MI/MCI with 1 mL of MeOH. Analytes were then eluted from the column, filtrated and collected in 
the glass vials for injection. 
MCI and MI were quantified using a liquid chromatography (Ultimate 3000 system - pump, 
autosampler and column compartment, Dionex Softron GmbH, Germering, Germany) – 
electrospray ionization ion trap tandem mass spectrometry (LC/ESI-MS/MS). Analytical 
parameters were adapted from the method of Speksnijder et al. (2010). 
A 10-µL of the extract was injected on the analytical column Agilent C18 Zorbax Eclipse plus 
(Rapid Resolution HT, Agilent Technologies, Morges, Switzerland; 4.6 x 50 mm, 1.8 µm). The 
column was maintained at 30 °C. The mobile phase consisted of 100% purified water (eluent A) 
and 100% MeOH (eluent B). The following solvent gradient program were used for elution in 15 
min: 20% eluent B ramping to 80% in 6 min, maintained at 80% for 4 min before returning to 
initial conditions of 20% from 10.1 to 12 min, and then the column was stabilized at 20% eluent 
B for 3 minutes. The ESI interface operated in positive mode for MCI ((m/z 150), MI (m/z 116) 
and isoproturon 6-d (m/z 212→171), no fragmentation for MCI and MI. Under these conditions, 
the retention times were 4.2, 2.1 and 8.2 min for MCI, MI, and isoproturon-6d, respectively. 
Quantification was based on peak area and calculated from standard calibration curves of the 
compound adjusted by the internal standard area (working range 0.1 to 50 µg/mL for MCI and 
MI). The limit of detection (LOD) was established on the basis of the signal to noise (s/n) ratio, 
and was 0.1 µg/mL for MCI and 1 µg/mL for MI. 
 
Data analysis 
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Skin permeation curves were created based on the MCI and MI concentrations in the reservoir 
liquid. Permeation rates (J), lag times (Tlag), and permeability coefficients (Kp) were calculated. 
As steady-state conditions were not reached in the experimental set-up except for MI in the 
cream MR Extra experiments, the apparent permeation coefficients were estimated from 
cumulative amount of MCI or MI absorbed per unit skin area per time course for each 
permeation cell. Means and standard deviations were calculated for the replicates. Individual 
permeation rates or J (µg/cm2/h) were determined by calculating the slope from the steepest 
linear part of the curve. Tlag (h) was obtained by extending the slope of the steepest linear part 
of the curve to the time axis. Kp (ng/cm) was calculated by dividing the J with the initial applied 
MCI or MI concentration (ng/cm3). The total amount of MCI or MI in the donor chamber at the 
end of the experiment, or the amount retained in the skin after washing were not quantified, 
thereby a percentage of absorption could not be calculated. 
 
Skin irritation test 
Epidermis changes following MCI and MI exposure were determined in full thickness viable skin 
exposed to MCI/MI at one of the following concentrations: 75/25, 150/50, 375/125, and 750/250 
µg/mL, and 500 µg/mL of MI. All experiments exposed the skin for 6 h (assuming 6-h exposure 
in a day) or 24 h (OECD guidelines). Full thickness skin as removed from patient, was divided in 
six large pieces, and placed in separate containers filled at the bottom with saline water 0.9% or 
RPMI media. A donor chamber from the diffusion cell (exposure area of 1.77 cm2) was placed 
on top of each skin piece where a finite dose was applied. By using the donor chamber as a 
template the exposure area could be defined. MCI/MI or MI solutions (n=5) were added (1 mL) 
directly in the donor chamber. Saline water or RPMI media were applied (1 mL) onto one skin 
piece which served as a negative control. After exposure, three skin biopsies were collected for 
each exposed area for histology preparation and interpretation. This experiment was repeated 
three times, each time with a different donor. 
 
Histology interpretation 
A Nikon 90i microscope was used to analyze the histological hematoxylin and eosin (H&E) 
stained skin slides. Each slide was randomly divided into ten section images. In each image, 
changes in the epidermis and in cell morphology were qualitatively assessed for spongiosis 
(accumulation of fluid between the keratinocytes and intercellular edema), vacuolization of the 
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basal layer (epidermolysis), apoptotic cells (bloated cells and shrunken nuclei (pyknosis) with a 
condensation of the chromatin), and suffering cells (big and ballooned nucleus) (Miles et al. 
2014). The intensity of the irritation was defined based on the criteria defined in Table 3 and as 
described in Miles et al. (2014). The exposed skin was compared to the negative controls from 
the same experiment to control potential damages due to experimental conditions. 
 
Results 
Percutaneous permeation characteristics 
The permeation coefficients calculated for MCI and MI are presented in Table 4. MCI was not 
detected in the reservoir liquid during the 20h experiment when it was applied as a standard 
diluted in water except at the greatest concentration applied (750 µg/mL) and then only after a 
long delay (Tlag > 8h). MCI was not detected in the reservoir liquid when applied as a cream. In 
commercial liquid formulations, MCI was detected between 3.5 and 5h; depending on the 
commercial formulations. MCI concentrations in the commercial products (pure vs diluted) did 
not influence permeation rates (J) nor Tlag as shown in Fig. 1 and Table 4. Overall, these results 
show that constituents in the formulations influence the percutaneous permeation of MCI. 
For MI, the cumulative mass permeation curves, J, and Tlag obtained for the commercial 
formulations and the aqueous solutions were quite similar, except for one commercial product 
(Parmetol® K40) (Fig. 2). For formulations and standard solutions, the permeation rates and 
delays (Tlag) were 0.5-1.5 µg/cm2/h and 0-0.2 h, respectively. This was also true following topical 
application of MI in the moisturizing cream and the hand cleaning gel (Table 4). From the cream 
MR Extra®, the cumulative mass permeation curve tapered off after 10 h indicating an apparent 
steady-state. Regarding dilution, it did not influence permeation rates or Tlag for MI. Permeability 
was inversely related with concentrations since J is not concentration-dependent; as indicated 
by a Kp value higher at lower concentrations and lower at higher concentrations. This was also 
observed for MCI. Overall, MI percutaneous permeation characteristics were distinctively 
different from MCI; constituents in the formulations did not seem to influence MI permeation 
through human skin as was observed for MCI, and MI permeated faster through human skin 
compared to MCI. 
 
Skin irritation 
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Table 5 presents the irritation intensity results of skin samples exposed to different MCI/MI 
aqueous solutions or formulations based on histological criteria presented in Table 3. No sign of 
irritation was observed for full thickness skin exposed to the two lowest concentrations (75/25, 
150/50 µg/mL) of MCI/MI for either 6 or 24 h, regardless of the medium used (physiological 
water or RPMI). Some mild signs of irritation were noted at the 375/125 µg/mL concentration; 
again for both exposure times and media. Moderate signs were noted at 750/250 µg/mL with the 
presence of apoptotic (a small, condensed and eosinophilic nucleus as chromatin is completely 
condensed inside it) and suffering (big and ballooned nucleus) cells (Fig. 3). No sign of irritation 
was observed for the greatest concentration of MI applied (500 µg/mL). 
Regarding skin recuperated after the flow-through diffusion cell experiments (800 µm thickness), 
some moderate irritation signs were noted for the undiluted formulation, Revaguard® and only 
mild irritation signs were observed when the formulation was diluted to 50% in water (Table 5). 
No irritation signs were observed for the cream tested (Priva Care®). We did not perform 
irritation tests on the other formulations due to monetary constraints. 
The skin barrier integrity was not affected by MCI/MI exposure, although moderate signs of 
irritation were identified by histology. TEWL measurements at the end of the experiments 
remained unchanged from the measurements taken at the start. Change in skin barrier integrity 
were only noted for the positive controls (skin exposed to sodium lauryl sulfate (SLS) 10%), 
which had strong signs of irritation using the histological criteria. 
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Discussion 
MI permeated through human fresh skin in less than 15 min (Tlag ≈ 0-0.2 h; Fig. 2) and with a 
relatively high permeation rate (J = 0.5-1.5 ug/cm2/h) regardless of the nature of the topical 
vehicle. On the contrary, MCI as a constituent in cream did not permeate skin and only after 
several hours in aqueous formulations. Thus, MCI permeation depends on type of vehicle (Table 
4). The severity of irritation caused by the MCI/MI mixture after 6h-exposure was dose 
dependant; producing moderate irritation at the highest dose (750/205 µg/mL), mild at the 
medium dose (375/125 µg/mL), and no irritation at the lowest dose (75/25 µg/mL). 
Unpublished data from Rohm and Haas (1989; 2003; 2005a; 2005b; 2005c) describe 
permeation of MCI and MI in in vitro experiments using rat or human post mortem skin occluded 
for 24h. A summary of the Rohm and Haas results has been compiled in Table 6 for an easier 
comparison (unpublished data reported by Burnett et al. (2010) and SCCS (2009)). These 
authors found that MI permeated easily though the skin. MCI in body lotion, facial cream, or at 
low concentrations in aqueous solutions (11.4 or 22.5 µg/mL) did not permeate through the skin 
after 24-h exposure. These findings are in accordance with the present study. However, MI 
permeation rates were 10 to 100 times faster in this study (J = 0.46 to 1.48 µg/cm2/h) compared 
to reported values from the Rohm and Haas studies (J = 0.07 to 0.037 µg/cm2/h). In addition to 
skin occlusion and skin thickness, experimental parameters can also influence the permeation 
rates, but since no information was provided in the report of Burnett et al. (2010) and SCCS 
(2009) for the Rohm and Haas’s unpublished studies, only general interpretations can be 
provided here. In general, chemicals permeate frozen skin faster compared to viable skin 
(Barbero and Frasch 2016), which was not what we observed for MI. All studies have shown 
that the permeation rate increased with increasing MI concentration applied as is to be expected 
for small water soluble molecules (Wester and Maibach 2010). 
MCI permeation was influenced by the topical vehicle while MI was not. MCI in shampoo, body 
lotion or cream did not permeate skin as was observed in both Rohm and Haas and this study. 
Aqueous solutions probably disrupt the SC intercellular lipid lamellae and create corneocyte 
separations as is known from ex vivo skin contact with water (Warner et al. 2003). The hydrogen 
bonding between MCI and MI with water can be an enhancer, which is reduced when added to 
cream. This is especially true for MCI with a higher Kow than MI (2.5 vs 0.3, respectively; Table 
1). The vehicle thus plays a role in skin permeation as previously reported by other studies 
(Gujjar and Banga 2014; Kanikkannan et al. 2000). 
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In vivo rat studies from Rohm and Haas (1982) and De Bethizy et al. (1986) highlighted a 
persistence of the two compounds in the skin application site for at least 96 h with an especially 
long elimination half-life for MCI (13.1 days). Rohm and Haas (1989; 2003; 2005a; 2005b; 
2005c) measured an important dose of MCI and a relatively high dose of MI in epidermis, 
suggesting that both compounds were retained in this skin layer (Table 6). However, Rohm and 
Haas studies noted no difference in the MCI doses measured in human SC or human 
epidermis, they remained similar for all tested solutions (around 8.9% and 50.3% of dose 
recovered for SC and epidermis, respectively). According to De Bethizy et al. (1986), it could be 
possible that the MCI retained in epidermis was not available for the systematic blood circulation 
and would be eliminated by normal desquamation of the epithelial cells. 
The mechanism of action regarding the reactivity toward nucleophilic materials for MCI and MI 
are fairly different, and this may explain the difference in permeation observed in this study. Both 
MCI and MI react with proteins. MCI reacts rapidly with most nucleophiles to form different 
stable protein adducts. MI can only react with thiol-containing peptides to form unstable protein 
adducts (Alvarez-Sánchez et al. 2004; Devos et al. 2015; Divkovic et al. 2005; Jayjock et al. 
1996; Mutschler et al. 2009). Thus stable MCI protein would retain the MCI in the skin and thus 
not allow it to permeate, while unstable MI only formed unstable protein adducts and could 
therefore permeate the skin. 
The hallmark of isothiazolinones is to kill microorganisms by interacting and oxidizing accessible 
cellular thiols (Du et al. 2002). By destroying the protein thiol groups, the cell undergoes cell 
death and produces free radicals (Williams 2007). Consequently, it is possible that MCI and MI 
interact with GSH of keratinocytes as GSH being the major source of free thiol group in the 
cells. This may in turn induce cell death by apoptosis or necrosis (Devos et al. 2015; Ettorre et 
al. 2003). Anselmi et al. (2002) reported apoptosis 24-h after exposure to 0.001 and 0.1% of 
MCI/MI in aqueous solutions, and necrosis at concentrations of 0.1 to 0.5% in their in vitro 
experiment using the human promyelocytic leukemia cell line (HL60). Similar results were 
observed in the study from Ettorre et al. (2003) using primary basal keratinocytes obtained from 
skin samples of patients during dermatologic operations. They observed an increase in reactive 
oxygen species (ROS) production related to an increase of MCI/MI concentrations. The authors 
suggested that low concentrations of MCI/MI induce apoptotic mechanisms while high 
concentrations activate necrotic mechanisms; and concluded that apoptosis was probably a 
keratinocytic response to less severe injuries than those inducing necrosis. This could explain 
our histology results as we observed focal spongiosis at 375/125 µg/mL of MCI/MI and suffering 
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and apoptotic cells at the highest concentration 750/250 µg/mL of MCI/MI in aqueous water 
(Table 5). Spongiosis development is characterized by apoptosis of single keratinocytes 
(Kerstan et al. 2011). 
Moreover, Williams (2007) emphasized that various adjuvants and surfactants added in 
formulations may increase the extent of cell death. This may explain the results for 
Revaguard®, pure or diluted, which differed significantly from the other commercial formulations 
tested. No skin irritation was observed in the histological evaluation of skin exposed to 71/35 
µg/mL of MCI/MI in aqueous solutions for 24h, while moderate irritation was noticed for pure 
Revaguard® (70/22 µg/mL of MCI/MI) and mild irritation for the 50% dilution of this product 
(35/11 µg/mL of MCI/MI). Consequently, the vehicle may have some influence on the 
permeation of MCI and MI through the skin as well as on skin irritation effects. 
Metabolism may occur in viable skin (Bronaugh 2005). MI metabolism has been observed in a 
rat study after administration of MI by gavage where main urinary metabolites detected were N-
methyl malonamic acid (NMMA), 3-mercapturic acid conjugate of 3-thiomethyl-N-methyl-
propionamide, and N-methyl-3-hydroxyl-propionamide (Burnett et al. 2010). Whether or not skin 
can metabolize MI is unknown and was not assessed in our skin permeation study. No studies 
on MCI metabolism were identified in the scientific literature. MCI and MI skin metabolism need 
to be addressed in future studies. 
MCI and MI are considered to be haptens; molecules with low molecular weight with 
electrophilic properties and chemically reactive that can form covalent bonds with nucleophilic 
materials thereby inducing sensitization (Alvarez-Sánchez et al. 2004; Devos et al. 2015; 
Divkovic et al. 2005). As of 2015, MCI is classified as an extreme skin sensitizer and MI a strong 
sensitizer (Devos et al. 2015; Roberts 2013). For this reason, the legislations do not allow the 
use of MCI and MI in rinse-off products at higher concentrations than 15 µg/mL of MCI/MI and 
up to 7.5 µg/mL for leave-on products. Although no sign of skin irritation was observed at these 
concentrations in this study, allergic reactions cannot be excluded as they can be induced at 
any concentrations. Since MI permeated through the skin quite easily and with a very short Tlag, 
it is recommended to limit exposure to MI and MCI. This is especially pertinent where topical 
vehicles may increase permeation. 
To attempt to relate permeation experiments and histology interpretations, several different 
concentrations of MCI/MI in aqueous water were tested. A quantitative dose response for the 
structural changes in the epidermis was obtained; however, the experiments did not include 
assays testing MI and MCI separately. This was due to the limited amount of skin samples that 
14 
we had access to perform the assays. Consequently, an influence of MCI or MI on the 
permeation coefficients when used in mixtures may not be excluded. Further studies should be 
performed to assess MCI and MI permeation separately as mixture ingredients may affect 
permeation profile of a compound by modifying properties of the stratum corneum and leading 
to an enhanced permeation of the compound (Ghafourian et al. 2010). 
 
Conclusion 
MI in formulations quickly permeated the skin with time lags less than an hour while MCI was 
much slower (>8h). MCI in formulations had permeation rates up to five times greater than for 
MI in the same product. Standard aqueous solutions of MCI/MI made in the laboratory, did not 
reflect formulation permeation characteristics; MI permeated skin slowly and after less than an 
hour exposure, while MCI was not detected after 20h of exposure. MCI in the two tested creams 
were not found to permeate skin. Some signs of irritation were observed by histology; especially 
at the highest MCI/MI concentrations (750/205 µg/mL) in aqueous solutions. The topical vehicle 
greatly influenced the MCI and MI permeations. It is therefore more relevant to test exposures to 
formulations than aqueous standard solutions. As allergic skin reactions may occur at any 
concentrations, it is recommended to limit exposure to MI and MCI. 
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Figure captions 
 
Fig. 1 – Cumulative amount of MCI (µg/cm2) measured in the receptor fluid over time (hours) 
following skin exposure to pure (Revaguard®, Permatol® K40) or diluted formulations 
(Revaguard®). 
 
Fig. 2 – Cumulative amount of MI (µg/cm2) measured in the receptor fluid over time (hours) 
following skin exposure to aqueous solutions (standard shown as solid triangles) and four 
different formulations (Permatol® K40 shown with solid diamonds, Revaguard® with white circle 
(pure) and black circle (diluted), Priva care® with black square and MR Extra® cream with white 
square). 
 
Fig. 3 – Irritation intensity results of skin sample exposed to 750/250 µg/mL of MCI/MI for 24 h 
compared to negative and positive controls based on histological criteria (spongiosis, 
epidermolysis, apoptotic and suffering cells). a) histological results for skin sample exposed to 
750/250 µg/mL of MCI/MI for 24 h (x10 enlargement); b) histological results for a negative 
control (skin exposed to physiological water for 24 h) (x40 enlargement); and c) histological 
results for a positive control (skin exposed to 10% of sodium lauryl sulphate (SLS) for 24 h) 
(x100 enlargement). 
 
 
 
 
 
